BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...stage example was Roche’s July deal that gave it an option to acquire remyelination company Convelo Therapeutics Inc....
BioCentury | Jul 16, 2019
Company News

Genentech adds three discovery partnerships to build out pipeline

..."Roche Broadens its BD Scope" ). MS is a focus of Genentech Inc.'s partnership with Convelo Therapeutics Inc....
...GPCR - G protein-coupled receptor; TM7SF2 - Transmembrane 7 superfamily member 2 Elizabeth S. Eaton, Staff Writer Convelo Therapeutics Inc. Genentech...
BioCentury | Oct 12, 2018
Targets & Mechanisms

Adult path for mitochondrial gene editing

...Derrick Rossi, a co-founder of Intellia Therapeutics Inc. who is now CEO of remyelination company Convelo Therapeutics Inc....
...their interest in mitochondrial gene editing. Companies and Institutions Mentioned Cellectis S.A. (NASDAQ:CLLS), Paris, France Convelo Therapeutics Inc....
BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

...multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo Therapeutics Inc....
...Development status Preclinical Patents Patent applications submitted by Case Western Reserve University and licensed to Convelo Therapeutics Inc....
...investigator Convelo Therapeutics; Derrick Rossi Companies and Institutions Mentioned Case Western Reserve University, Cleveland, Ohio Convelo therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Neuro play Convelo emerges from stealth

...screening systems, remyelination platforms and candidates. Convelo Therapeutics Inc., Cleveland, Ohio Business: Neurology, Autoimmune Chris Lieu Case Western Reserve University Convelo Therapeutics Inc. Multiple...
Items per page:
1 - 5 of 5
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...stage example was Roche’s July deal that gave it an option to acquire remyelination company Convelo Therapeutics Inc....
BioCentury | Jul 16, 2019
Company News

Genentech adds three discovery partnerships to build out pipeline

..."Roche Broadens its BD Scope" ). MS is a focus of Genentech Inc.'s partnership with Convelo Therapeutics Inc....
...GPCR - G protein-coupled receptor; TM7SF2 - Transmembrane 7 superfamily member 2 Elizabeth S. Eaton, Staff Writer Convelo Therapeutics Inc. Genentech...
BioCentury | Oct 12, 2018
Targets & Mechanisms

Adult path for mitochondrial gene editing

...Derrick Rossi, a co-founder of Intellia Therapeutics Inc. who is now CEO of remyelination company Convelo Therapeutics Inc....
...their interest in mitochondrial gene editing. Companies and Institutions Mentioned Cellectis S.A. (NASDAQ:CLLS), Paris, France Convelo Therapeutics Inc....
BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

...multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo Therapeutics Inc....
...Development status Preclinical Patents Patent applications submitted by Case Western Reserve University and licensed to Convelo Therapeutics Inc....
...investigator Convelo Therapeutics; Derrick Rossi Companies and Institutions Mentioned Case Western Reserve University, Cleveland, Ohio Convelo therapeutics Inc....
BioCentury | Jul 27, 2018
Company News

Neuro play Convelo emerges from stealth

...screening systems, remyelination platforms and candidates. Convelo Therapeutics Inc., Cleveland, Ohio Business: Neurology, Autoimmune Chris Lieu Case Western Reserve University Convelo Therapeutics Inc. Multiple...
Items per page:
1 - 5 of 5